Insider Buying: Harvard Bioscience, Inc. (NASDAQ:HBIO) Director Purchases $98,989.20 in Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Director Katherine A. Eade acquired 39,915 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was bought at an average price of $2.48 per share, with a total value of $98,989.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

NASDAQ:HBIO opened at $2.48 on Thursday. Harvard Bioscience, Inc. has a 1 year low of $1.51 and a 1 year high of $6.70. The company has a current ratio of 2.22, a quick ratio of 1.12 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $95.88 million, a PE ratio of 16.53 and a beta of 1.51. The firm has a 50-day simple moving average of $2.13.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. Harvard Bioscience had a positive return on equity of 5.22% and a negative net margin of 0.46%. The firm had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $29.30 million. As a group, equities analysts expect that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current year.

HBIO has been the subject of a number of research analyst reports. Benchmark reissued a “buy” rating on shares of Harvard Bioscience in a research note on Friday, July 19th. Janney Montgomery Scott cut Harvard Bioscience from a “buy” rating to a “neutral” rating and set a $2.00 target price for the company. in a research note on Monday, July 8th. Zacks Investment Research cut Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Finally, ValuEngine raised Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Monday.

Large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its position in shares of Harvard Bioscience by 2.5% during the fourth quarter. BlackRock Inc. now owns 3,067,176 shares of the medical instruments supplier’s stock worth $9,754,000 after buying an additional 73,423 shares during the period. Dalton Greiner Hartman Maher & Co. boosted its position in shares of Harvard Bioscience by 1,164.5% during the second quarter. Dalton Greiner Hartman Maher & Co. now owns 1,117,421 shares of the medical instruments supplier’s stock worth $2,235,000 after buying an additional 1,029,052 shares during the period. Acadian Asset Management LLC boosted its position in shares of Harvard Bioscience by 36.5% during the second quarter. Acadian Asset Management LLC now owns 1,052,028 shares of the medical instruments supplier’s stock worth $2,103,000 after buying an additional 281,293 shares during the period. Renaissance Technologies LLC boosted its position in shares of Harvard Bioscience by 45.0% during the second quarter. Renaissance Technologies LLC now owns 901,000 shares of the medical instruments supplier’s stock worth $1,802,000 after buying an additional 279,500 shares during the period. Finally, Foundry Partners LLC boosted its position in shares of Harvard Bioscience by 37.5% during the second quarter. Foundry Partners LLC now owns 720,540 shares of the medical instruments supplier’s stock worth $1,441,000 after buying an additional 196,375 shares during the period. 76.39% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Featured Story: Producer Price Index (PPI)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.